STAA logo

STAAR SURGICAL CO

STAANASDAQ
๐Ÿ† #2252 by market capEarnings Nov 4 ยท PostUS Equity
$25.24โ–ฒ $0.63 (+2.56%)
๐ŸŒ… Pre-market$25.12โ–ผ 0.48%Regular close ยท extended-hours price shown
๐Ÿ””
Track STAA
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 2.6%
7dโ–ฒ 11.8%
14dโ–ฒ 18.7%
30dโ–ฒ 11.5%
ytdโ–ฒ 9.4%
1yโ–ผ 4.9%
๐ŸฆMarket Cap
$1.27B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
51.3%
High Growth
๐Ÿ“ŠGross Margin
76.6%
High
๐Ÿ’ตFCF Margin
6.2%
Moderate
โš–๏ธP/S Ratio
3.6x
Fair
Otter Score
76
Strong

Trading Snapshot

Day Range
$24.61 โ€“ $25.52
52-Week Range
$15.59 โ€“ $35.87
Volume (shares)
453,587
Avg Volume (shares)
โ€”
Shares Outstanding
50.1M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$239M
Last Q Revenue
$94M
P/E Ratio
317.0
P/S Ratio
3.6x
EPS (TTM)
$0.07
Dividend Yield
โ€”
Dilution (1yr)
+4.0%
STAA logo

STAAR SURGICAL CO

STAA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$239Mโ–ผ โˆ’23.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
76.2%โ–ผ โˆ’0.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$46Mโ–ฒ +264.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$40Mโ–ฒ +422.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
51.5Mโ–ฒ +4.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$113Mโ–ผ โˆ’$24M YoY
StockOtter ยท stockotter.space

About STAAR SURGICAL CO

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Strong
76/100

Analyst Ratings

โ“˜
Consensus
Buy
18 analysts
Strong Buy4
Buy5
Hold8
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Business Wireยท1d ago

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (โ€œSTAARโ€ or the โ€œCompanyโ€) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamerยฎ Lenses (EVO ICLโ„ข) for vision correctio

Zacks Investment Researchยท1d ago

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWireยท8d ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties. If you are a current sh

Defense Worldยท13d ago

B. Riley Wealth Advisors Inc. Makes New $546,000 Investment in STAAR Surgical Company $STAA

B. Riley Wealth Advisors Inc. bought a new stake in STAAR Surgical Company (NASDAQ: STAA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2

GuruFocusยท21d ago

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

STAAR Surgical Company (รขย€ยœSTAARรขย€ย or the รขย€ยœCompanyรขย€ย) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamerร‚ Lenses

The Motley FoolยทSep 29

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

That pundit now believes it's a buy. He cited positive sales momentum, especially in a key market overseas.